AstraZeneca’s R&D collaboration with CSPC Pharmaceutical Group includes an oral small molecule for immunological diseases, which would offer a dosing edge over currently available injectable medications. The agreement follows a 2024 licensing agreement that granted AstraZeneca rights to an oral CSPC drug candidate in development for a metabolic disorder.
In the past, arbitrary maintenance schedules and planned downtime were necessary expenses. Now we have the tools to think and work differently
Who accredits health plans for mental health parity compliance? Learn about the only organization that offers this program to ensure your members get equitable care.
BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins.
Bristol Myers Squibb is licensing global rights to a Philochem program in development for both diagnostic imaging and targeted treatment of prostate cancer. It follows the pharma giant’s entry into radiopharmaceuticals via the $4.1 billion acquisition of RayzeBio last year.
The letter is an extraordinary rebuke of the Trump administration’s actions against the NIH, which include: terminating hundreds of grants funding scientific and biomedical research; firing more than 1,000 employees this year; and moving to end billions in funds to partner institutions overseas.
Antares Therapeutics spun off of Scorpion Therapeutics, a clinical-stage biotech that Eli Lilly acquired earlier this year. Like Scorpion, Antares is developing small molecules that go after undruggable targets in cancer.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.
Business banking provider* Mercury sponsored a webinar discussing early stage investment topics with venture capitalists such as grant funding secrets, capital valuation, the role of AI in life sciences, and more.
Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, permitting longer dosing intervals. Lilly plans to apply the technology to its metabolic medicines; the deal follows a similar move Novo Nordisk starting an alliance with Ascendis.
A one-size fits most approach to clinical trial recruitment is no longer effective. A webinar discussion emphasized the need for patient-level data to shape each phase of a drug’s lifecycle, from clinical development to market access.
Healthcare supplies have a direct correlation to the safety and national security of Americans as any disruption to availability jeopardizes the health of our nation. Americans cannot forego access to lifesaving medications.
Get your IV treatment from wherever you are. These top companies provide mobile IV therapy administered by experienced nurses in NYC and beyond.
Kura Oncology’s ziftomenib addresses a specific genetic mutation present in about 30% of cases of acute myeloid leukemia. Data from the drug’s pivotal Phase 2 test were presented during the annual meeting of the American Society of Clinical Oncology.
This is the moment to build flexible plans. Organizations that develop operational models with built-in scenario planning, ready to scale up or down as the capital environment shifts, will be positioned to take advantage of greater investment when it comes.
Merck KGaA’s pimicotinib led to statistically significant improvement on multiple measures of its Phase 3 test in tenosynovial giant cell tumor, positioning the drug to potentially compete with medications from Daiichi Sankyo and Ono Pharma. The Phase 3 results were presented during the annual meeting of the American Society of Clinical Oncology.
Astellas Pharma gets global rights to an Evopoint Biosciences antibody drug conjugate that targets Claudin 18.2. Last year, Astellas’s antibody drug Vyloy became the first FDA-approved therapy for this target.
In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid-19, the FDA said its policy will compel generation of more evidence for these groups. Our roundup of regulatory news includes notable firsts for Alzheimer’s diagnosis and migraine treatment.